BioSpace News Archive

BD, a leading global medical technology company, and CerTest Biotec announced their newly developed molecular polymerase chain reaction assay for monkeypox virus is now commercially available globally, including in the United States, for research use only applications by laboratories.

Retinoblastoma is a cancer of the eye that occurs in infants and toddlers and can lead to loss of vision, loss of one or both eyes, and even death.

Nanoscope Therapeutics Inc. today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting, taking place Thursday, September 29, 2022, in Chicago, IL.

HTG Molecular Diagnostics, Inc. today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

Daxor Corporation today announces it will be attending the Annual Scientific Meeting of the Heart Failure Society of America (HFSA) which brings together the world’s leading experts in heart failure at the Gaylord National Harbor in Washington, DC from September 30th thru October 3rd, 2022.

Cabaletta Bio, Inc. today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 4:00 p.m. ET in New York, NY.

Surrozen, Inc. announced today the publication of an article by Surrozen scientists in the journal Translational Vision Science and Technology.

Erasca, Inc. today announced its participation in the Bank of America Securities Precision Oncology Conference.

eFFECTOR Therapeutics, Inc. today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.

Brii Biosciences Limited today announced top-line results from a Phase 1 study evaluating its long-acting, single-injection therapy, BRII-296, in development for the treatment of postpartum depression (PPD).